BML（BMZ）株式概要BML, Inc.は日本でラボラトリー検査と関連サービスを提供している。 詳細BMZ ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績4/6財務の健全性6/6配当金5/6報酬当社が推定した公正価値より57.4%で取引されている 収益は年間7.78%増加すると予測されています 過去1年間で収益は22.6%増加しました 3.48%の安定した配当金を支払う リスク分析リスクチェックの結果、BMZ 、リスクは検出されなかった。すべてのリスクチェックを見るBMZ Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,227 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,227 investors already sharing narrativesYour Fair Value€Current Price€19.606.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0179b2016201920222025202620282031Revenue JP¥177.3bEarnings JP¥9.2bAdvancedSet Fair ValueView all narrativesBML, Inc. 競合他社Fresenius Medical CareSymbol: XTRA:FMEMarket cap: €11.1bRHÖN-KLINIKUMSymbol: XTRA:RHKMarket cap: €1.0bPaul HartmannSymbol: DB:PHH2Market cap: €724.6mM1 KlinikenSymbol: XTRA:M12Market cap: €356.6m価格と性能株価の高値、安値、推移の概要BML過去の株価現在の株価JP¥19.6052週高値JP¥23.6052週安値JP¥18.40ベータ0.241ヶ月の変化-1.01%3ヶ月変化-1.51%1年変化-1.01%3年間の変化9.50%5年間の変化-46.60%IPOからの変化-0.76%最新ニュースReported Earnings • 22hFirst quarter 2027 earnings released: EPS: JP¥52.82 (vs JP¥47.74 in 1Q 2026)First quarter 2027 results: EPS: JP¥52.82 (up from JP¥47.74 in 1Q 2026). Revenue: JP¥39.0b (up 2.7% from 1Q 2026). Net income: JP¥1.98b (up 6.3% from 1Q 2026). Profit margin: 5.1% (up from 4.9% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Declared Dividend • Jul 26Final dividend of JP¥62.50 announcedShareholders will receive a dividend of JP¥62.50. Ex-date: 29th September 2026 Payment date: 2nd December 2026 Dividend yield will be 331%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 03BML, Inc. to Report Q1, 2027 Results on Aug 07, 2026BML, Inc. announced that they will report Q1, 2027 results on Aug 07, 2026Reported Earnings • May 14Full year 2026 earnings released: EPS: JP¥204 (vs JP¥161 in FY 2025)Full year 2026 results: EPS: JP¥204 (up from JP¥161 in FY 2025). Revenue: JP¥150.3b (up 4.9% from FY 2025). Net income: JP¥7.75b (up 24% from FY 2025). Profit margin: 5.2% (up from 4.4% in FY 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • May 13BML, Inc., Annual General Meeting, Jun 26, 2026BML, Inc., Annual General Meeting, Jun 26, 2026.お知らせ • May 09BML, Inc. to Report Fiscal Year 2026 Results on May 13, 2026BML, Inc. announced that they will report fiscal year 2026 results on May 13, 2026最新情報をもっと見るRecent updatesReported Earnings • 22hFirst quarter 2027 earnings released: EPS: JP¥52.82 (vs JP¥47.74 in 1Q 2026)First quarter 2027 results: EPS: JP¥52.82 (up from JP¥47.74 in 1Q 2026). Revenue: JP¥39.0b (up 2.7% from 1Q 2026). Net income: JP¥1.98b (up 6.3% from 1Q 2026). Profit margin: 5.1% (up from 4.9% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Declared Dividend • Jul 26Final dividend of JP¥62.50 announcedShareholders will receive a dividend of JP¥62.50. Ex-date: 29th September 2026 Payment date: 2nd December 2026 Dividend yield will be 331%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 03BML, Inc. to Report Q1, 2027 Results on Aug 07, 2026BML, Inc. announced that they will report Q1, 2027 results on Aug 07, 2026Reported Earnings • May 14Full year 2026 earnings released: EPS: JP¥204 (vs JP¥161 in FY 2025)Full year 2026 results: EPS: JP¥204 (up from JP¥161 in FY 2025). Revenue: JP¥150.3b (up 4.9% from FY 2025). Net income: JP¥7.75b (up 24% from FY 2025). Profit margin: 5.2% (up from 4.4% in FY 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • May 13BML, Inc., Annual General Meeting, Jun 26, 2026BML, Inc., Annual General Meeting, Jun 26, 2026.お知らせ • May 09BML, Inc. to Report Fiscal Year 2026 Results on May 13, 2026BML, Inc. announced that they will report fiscal year 2026 results on May 13, 2026Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 30 June 2026. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.8%).Reported Earnings • Feb 08Third quarter 2026 earnings released: EPS: JP¥62.19 (vs JP¥47.02 in 3Q 2025)Third quarter 2026 results: EPS: JP¥62.19 (up from JP¥47.02 in 3Q 2025). Revenue: JP¥38.8b (up 4.4% from 3Q 2025). Net income: JP¥2.34b (up 28% from 3Q 2025). Profit margin: 6.0% (up from 4.9% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Declared Dividend • Dec 03First half dividend of JP¥60.00 announcedShareholders will receive a dividend of JP¥60.00. Ex-date: 30th March 2026 Payment date: 30th June 2026 Dividend yield will be 293%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (50% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Nov 09Second quarter 2026 earnings released: EPS: JP¥61.81 (vs JP¥44.08 in 2Q 2025)Second quarter 2026 results: EPS: JP¥61.81 (up from JP¥44.08 in 2Q 2025). Revenue: JP¥37.6b (up 5.1% from 2Q 2025). Net income: JP¥2.36b (up 37% from 2Q 2025). Profit margin: 6.3% (up from 4.8% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 03 December 2025. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (2.5%).お知らせ • Sep 03+ 1 more updateBML, Inc. to Report Q3, 2026 Results on Feb 06, 2026BML, Inc. announced that they will report Q3, 2026 results on Feb 06, 2026Reported Earnings • Aug 10First quarter 2026 earnings released: EPS: JP¥47.74 (vs JP¥43.79 in 1Q 2025)First quarter 2026 results: EPS: JP¥47.74 (up from JP¥43.79 in 1Q 2025). Revenue: JP¥38.0b (up 6.8% from 1Q 2025). Net income: JP¥1.86b (up 9.1% from 1Q 2025). Profit margin: 4.9% (up from 4.8% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Declared Dividend • Jul 09Final dividend of JP¥60.00 announcedShareholders will receive a dividend of JP¥60.00. Ex-date: 29th September 2025 Payment date: 3rd December 2025 Dividend yield will be 321%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥161 (vs JP¥155 in FY 2024)Full year 2025 results: EPS: JP¥161 (up from JP¥155 in FY 2024). Revenue: JP¥143.2b (up 3.8% from FY 2024). Net income: JP¥6.26b (up 3.8% from FY 2024). Profit margin: 4.4% (in line with FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.お知らせ • Jun 03BML, Inc. to Report Q1, 2026 Results on Aug 08, 2025BML, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025Buy Or Sell Opportunity • May 14Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.0% to €16.80. The fair value is estimated to be €21.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 65%. Revenue is forecast to grow by 6.2% in 2 years. Earnings are forecast to grow by 8.6% in the next 2 years.Reported Earnings • May 11Full year 2025 earnings released: EPS: JP¥161 (vs JP¥155 in FY 2024)Full year 2025 results: EPS: JP¥161 (up from JP¥155 in FY 2024). Revenue: JP¥143.2b (up 3.8% from FY 2024). Net income: JP¥6.26b (up 3.8% from FY 2024). Profit margin: 4.4% (in line with FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.お知らせ • May 09BML, Inc., Annual General Meeting, Jun 27, 2025BML, Inc., Annual General Meeting, Jun 27, 2025.Upcoming Dividend • Mar 21Upcoming dividend of JP¥70.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 30 June 2025. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 4.7%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (2.7%).お知らせ • Mar 04BML, Inc. to Report Fiscal Year 2025 Results on May 09, 2025BML, Inc. announced that they will report fiscal year 2025 results on May 09, 2025New Risk • Feb 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risk Paying a dividend despite having no free cash flows.Reported Earnings • Feb 09Third quarter 2025 earnings released: EPS: JP¥47.02 (vs JP¥47.58 in 3Q 2024)Third quarter 2025 results: EPS: JP¥47.02 (down from JP¥47.58 in 3Q 2024). Revenue: JP¥37.2b (up 6.0% from 3Q 2024). Net income: JP¥1.83b (down 1.1% from 3Q 2024). Profit margin: 4.9% (down from 5.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: JP¥44.08 (vs JP¥40.00 in 2Q 2024)Second quarter 2025 results: EPS: JP¥44.08 (up from JP¥40.00 in 2Q 2024). Revenue: JP¥35.8b (up 2.7% from 2Q 2024). Net income: JP¥1.72b (up 10% from 2Q 2024). Profit margin: 4.8% (up from 4.5% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 20Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 52% but the company is not cash flow positive. Trailing yield: 3.7%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.0%).お知らせ • Aug 28+ 1 more updateBML, Inc. to Report Q2, 2025 Results on Nov 08, 2024BML, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: JP¥43.79 (vs JP¥46.08 in 1Q 2024)First quarter 2025 results: EPS: JP¥43.79 (down from JP¥46.08 in 1Q 2024). Revenue: JP¥35.6b (flat on 1Q 2024). Net income: JP¥1.71b (down 5.0% from 1Q 2024). Profit margin: 4.8% (down from 5.1% in 1Q 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.お知らせ • Jun 06BML, Inc. to Report Q1, 2025 Results on Aug 09, 2024BML, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024Reported Earnings • May 13Full year 2024 earnings released: EPS: JP¥155 (vs JP¥396 in FY 2023)Full year 2024 results: EPS: JP¥155 (down from JP¥396 in FY 2023). Revenue: JP¥138.0b (down 14% from FY 2023). Net income: JP¥6.03b (down 61% from FY 2023). Profit margin: 4.4% (down from 9.8% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.お知らせ • May 12BML, Inc., Annual General Meeting, Jun 27, 2024BML, Inc., Annual General Meeting, Jun 27, 2024.Upcoming Dividend • Mar 21Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 42% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (3.2%).お知らせ • Mar 02BML, Inc. to Report Fiscal Year 2024 Results on May 10, 2024BML, Inc. announced that they will report fiscal year 2024 results on May 10, 2024New Risk • Feb 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.3% net profit margin).Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥47.58 (vs JP¥76.57 in 3Q 2023)Third quarter 2024 results: EPS: JP¥47.58 (down from JP¥76.57 in 3Q 2023). Revenue: JP¥35.1b (down 13% from 3Q 2023). Net income: JP¥1.86b (down 38% from 3Q 2023). Profit margin: 5.3% (down from 7.5% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.4% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 16% per year.New Risk • Dec 17New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.9% net profit margin).Reported Earnings • Nov 12Second quarter 2024 earnings released: EPS: JP¥40.00 (vs JP¥143 in 2Q 2023)Second quarter 2024 results: EPS: JP¥40.00 (down from JP¥143 in 2Q 2023). Revenue: JP¥34.8b (down 19% from 2Q 2023). Net income: JP¥1.56b (down 72% from 2Q 2023). Profit margin: 4.5% (down from 13% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 1.0% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 21Upcoming dividend of JP¥40.00 per share at 2.9% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 04 December 2023. Payout ratio is a comfortable 25% and the cash payout ratio is 94%. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.9%).お知らせ • Aug 30BML, Inc. to Report Q2, 2024 Results on Feb 09, 2024BML, Inc. announced that they will report Q2, 2024 results on Feb 09, 2024Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥46.08 (vs JP¥119 in 1Q 2023)First quarter 2024 results: EPS: JP¥46.08 (down from JP¥119 in 1Q 2023). Revenue: JP¥35.3b (down 13% from 1Q 2023). Net income: JP¥1.80b (down 62% from 1Q 2023). Profit margin: 5.1% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • May 31BML, Inc. to Report Q1, 2024 Results on Aug 10, 2023BML, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023Reported Earnings • May 16Full year 2023 earnings released: EPS: JP¥396 (vs JP¥833 in FY 2022)Full year 2023 results: EPS: JP¥396 (down from JP¥833 in FY 2022). Revenue: JP¥159.5b (down 14% from FY 2022). Net income: JP¥15.6b (down 54% from FY 2022). Profit margin: 9.8% (down from 18% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • May 14BML, Inc., Annual General Meeting, Jun 29, 2023BML, Inc., Annual General Meeting, Jun 29, 2023.Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per share at 2.6% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (3.4%).Buying Opportunity • Feb 28Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.2%. The fair value is estimated to be €27.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 52%. For the next 3 years, revenue is forecast to decline by 0.8% per annum. Earnings is also forecast to decline by 6.7% per annum over the same time period.Reported Earnings • Feb 13Third quarter 2023 earnings released: EPS: JP¥76.57 (vs JP¥131 in 3Q 2022)Third quarter 2023 results: EPS: JP¥76.57 (down from JP¥131 in 3Q 2022). Revenue: JP¥40.2b (down 1.9% from 3Q 2022). Net income: JP¥3.01b (down 43% from 3Q 2022). Profit margin: 7.5% (down from 13% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Feb 11BML, Inc. (TSE:4694) announces an Equity Buyback for 350,000 shares, representing 0.89% for ¥1,000 million.BML, Inc. (TSE:4694) announces a share repurchase program. Under the program, the company will repurchase up to 350,000 shares, representing 0.89% of its issued share capital for ¥1,000 million. The purpose of the program is to improve capital efficiency and enhance shareholder returns. The program is valid till April 30, 2023. As of January 31, 2023, the company had 39,279,662 shares issued (excluding treasury stock) and 3,333,964 shares in treasury.Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥143 (vs JP¥217 in 2Q 2022)Second quarter 2023 results: EPS: JP¥143 (down from JP¥217 in 2Q 2022). Revenue: JP¥43.2b (down 11% from 2Q 2022). Net income: JP¥5.61b (down 36% from 2Q 2022). Profit margin: 13% (down from 18% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Outside Director Shigeru Osawa was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 02 December 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.9%).お知らせ • Aug 31+ 1 more updateBML, Inc. to Report Q2, 2023 Results on Nov 11, 2022BML, Inc. announced that they will report Q2, 2023 results on Nov 11, 2022Reported Earnings • Aug 11First quarter 2023 earnings released: EPS: JP¥119 (vs JP¥244 in 1Q 2022)First quarter 2023 results: EPS: JP¥119 (down from JP¥244 in 1Q 2022). Revenue: JP¥40.5b (down 14% from 1Q 2022). Net income: JP¥4.72b (down 53% from 1Q 2022). Profit margin: 12% (down from 21% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the next year, revenue is expected to shrink by 20% compared to a 2.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 02BML, Inc. to Report Q1, 2023 Results on Aug 10, 2022BML, Inc. announced that they will report Q1, 2023 results on Aug 10, 2022Reported Earnings • May 16Full year 2022 earnings released: EPS: JP¥833 (vs JP¥337 in FY 2021)Full year 2022 results: EPS: JP¥833 (up from JP¥337 in FY 2021). Revenue: JP¥186.1b (up 34% from FY 2021). Net income: JP¥33.7b (up 146% from FY 2021). Profit margin: 18% (up from 9.9% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 24% compared to a 5.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • May 15BML, Inc., Annual General Meeting, Jun 29, 2022BML, Inc., Annual General Meeting, Jun 29, 2022.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. 3 independent directors (5 non-independent directors). Managing Executive Officer & Director Masato Chikira was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 08BML, Inc. to Report Fiscal Year 2022 Results on May 13, 2022BML, Inc. announced that they will report fiscal year 2022 results on May 13, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥85.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (2.6%).お知らせ • Mar 03BML, Inc. (TSE:4694) announces an Equity Buyback for 1,000,000 shares, representing 2.49% for ¥3,000 million.BML, Inc. (TSE:4694) announces a share repurchase program. Under the program, the company will repurchase up to 1,000,000 shares, representing 2.49% of its issued share capital for ¥3,000 million. The purpose of the program is to return of profits to shareholders as one of the important management issues, implement agile capital policies in response to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The program is valid till August 31, 2022. As of January 31, 2022, the company had 40,206,024 shares issued (excluding treasury stock) and 3,808,702 shares in treasury.Reported Earnings • Feb 10Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥131 (up from JP¥126 in 3Q 2021). Revenue: JP¥41.0b (up 6.6% from 3Q 2021). Net income: JP¥5.29b (up 3.1% from 3Q 2021). Profit margin: 13% (in line with 3Q 2021). Revenue exceeded analyst estimates by 7.7%. Over the next year, revenue is expected to shrink by 18% compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS JP¥217 (vs JP¥83.75 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥48.6b (up 44% from 2Q 2021). Net income: JP¥8.82b (up 159% from 2Q 2021). Profit margin: 18% (up from 10% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Sep 22Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 02 December 2021. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.3%).Reported Earnings • Aug 13First quarter 2022 earnings released: EPS JP¥244 (vs JP¥2.73 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥47.1b (up 80% from 1Q 2021). Net income: JP¥9.94b (up JP¥9.83b from 1Q 2021). Profit margin: 21% (up from 0.4% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 15Full year 2021 earnings released: EPS JP¥337 (vs JP¥151 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥138.6b (up 15% from FY 2020). Net income: JP¥13.7b (up 115% from FY 2020). Profit margin: 9.9% (up from 5.3% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Mar 23Upcoming Dividend of JP¥50.00 Per ShareWill be paid on the 29th of June to those who are registered shareholders by the 30th of March. The trailing yield of 1.4% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (2.4%).Reported Earnings • Feb 13Third quarter 2021 earnings released: EPS JP¥126 (vs JP¥40.86 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥38.5b (up 24% from 3Q 2020). Net income: JP¥5.14b (up 195% from 3Q 2020). Profit margin: 13% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Feb 13Revenue beats expectationsRevenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 1.5%, compared to a 3.5% growth forecast for the Healthcare industry in Germany.Is New 90 Day High Low • Feb 11New 90-day high: €29.70The company is up 18% from its price of €25.18 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.25 per share.Is New 90 Day High Low • Jan 21New 90-day high: €28.58The company is up 19% from its price of €24.11 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.80 per share.お知らせ • Dec 13BML, Inc. to Report Q3, 2021 Results on Feb 10, 2021BML, Inc. announced that they will report Q3, 2021 results on Feb 10, 2021Is New 90 Day High Low • Dec 12New 90-day high: €27.92The company is up 22% from its price of €22.94 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.58 per share.Is New 90 Day High Low • Nov 21New 90-day high: €26.48The company is up 21% from its price of €21.82 on 21 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.58 per share.Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectationsRevenue exceeded analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 4.3%, compared to a 4.4% growth forecast for the Healthcare industry in Germany.Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS JP¥83.75The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥33.7b (up 8.5% from 2Q 2020). Net income: JP¥3.40b (up 76% from 2Q 2020). Profit margin: 10% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Sep 22New 90-day high: €24.23The company is up 2.0% from its price of €23.78 on 24 June 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.04 per share.お知らせ • Aug 30BML, Inc. to Report Q2, 2021 Results on Nov 10, 2020BML, Inc. announced that they will report Q2, 2021 results on Nov 10, 2020株主還元BMZDE HealthcareDE 市場7D1.0%2.4%2.2%1Y-1.0%6.8%3.5%株主還元を見る業界別リターン: BMZ過去 1 年間で6.8 % の収益を上げたGerman Healthcare業界を下回りました。リターン対市場: BMZは、過去 1 年間で3.5 % のリターンを上げたGerman市場を下回りました。価格変動Is BMZ's price volatile compared to industry and market?BMZ volatilityBMZ Average Weekly Movement3.3%Healthcare Industry Average Movement5.6%Market Average Movement5.3%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: BMZ 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: BMZの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19554,612Kensuke Kondowww.bml.co.jp株式会社ビー・エム・エルは日本で検体検査および関連サービスを提供している。生化学・血液学的検査、RIA・細胞・免疫・DNA分析を含む特殊検体検査、医学会・薬学会・団体向けの微生物学的検査、腫瘍学・感染症学・糖尿病学・高血圧学・アレルギー学・遺伝子学などの検体検査、選別から分注までの前処理とその後の検査手順を自動化するフロンティア・シンフォニー自動化システムの開発など、さまざまな検体検査を提供している。また、医療情報をネットワーク化する電子カルテなどの医療情報システムサービスや予防医学サービスも提供している。さらに、食品衛生管理などの食品衛生検査や、原材料や調理・加工食品の微生物検査受託サービス、食品加工施設や厨房の環境衛生検査、微生物検査サービス、遺伝子組換え生物の評価などの食品加工サービスも提供している。さらに、飲料水や廃水の検査、エチレンオキシドガス、ホルムアルデヒド、有機溶剤、粉塵の測定などの作業環境サービス、室内汚染物質やその他の室内環境変数の測定を含む環境モニタリング、生物学的ダイオキシンのモニタリングサービスも提供している。また、残留農薬分析サービス、う蝕・歯周病検査サービス、医薬品承認コンサルティングサービス、製薬メーカー向け調査分析サービス、ヒトゲノム解析サービス、遺伝子発現解析・感染症感受性遺伝子検査サービスなども提供している。同社は1955年に設立され、東京に本社を置いている。もっと見るBML, Inc. 基礎のまとめBML の収益と売上を時価総額と比較するとどうか。BMZ 基礎統計学時価総額€738.58m収益（TTM）€43.17m売上高(TTM)€830.27m17.1xPER（株価収益率0.9xP/SレシオBMZ は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BMZ 損益計算書（TTM）収益JP¥151.27b売上原価JP¥102.01b売上総利益JP¥49.26bその他の費用JP¥41.40b収益JP¥7.87b直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）209.85グロス・マージン32.57%純利益率5.20%有利子負債／自己資本比率0%BMZ の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.5%現在の配当利回り60%配当性向BMZ 配当は確実ですか？BMZ 配当履歴とベンチマークを見るBMZ 、いつまでに購入すれば配当金を受け取れますか？BML 配当日配当落ち日Sep 29 2026配当支払日Dec 02 2026配当落ちまでの日数50 days配当支払日までの日数114 daysBMZ 配当は確実ですか？BMZ 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 23:33終値2026/08/07 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BML, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Mitsuko MiyasakoBarclaysYuki YamazakiDaiwa Securities Co. Ltd.Masao YoshidaIchiyoshi Research Institute Inc.4 その他のアナリストを表示
Reported Earnings • 22hFirst quarter 2027 earnings released: EPS: JP¥52.82 (vs JP¥47.74 in 1Q 2026)First quarter 2027 results: EPS: JP¥52.82 (up from JP¥47.74 in 1Q 2026). Revenue: JP¥39.0b (up 2.7% from 1Q 2026). Net income: JP¥1.98b (up 6.3% from 1Q 2026). Profit margin: 5.1% (up from 4.9% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Declared Dividend • Jul 26Final dividend of JP¥62.50 announcedShareholders will receive a dividend of JP¥62.50. Ex-date: 29th September 2026 Payment date: 2nd December 2026 Dividend yield will be 331%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 03BML, Inc. to Report Q1, 2027 Results on Aug 07, 2026BML, Inc. announced that they will report Q1, 2027 results on Aug 07, 2026
Reported Earnings • May 14Full year 2026 earnings released: EPS: JP¥204 (vs JP¥161 in FY 2025)Full year 2026 results: EPS: JP¥204 (up from JP¥161 in FY 2025). Revenue: JP¥150.3b (up 4.9% from FY 2025). Net income: JP¥7.75b (up 24% from FY 2025). Profit margin: 5.2% (up from 4.4% in FY 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • May 13BML, Inc., Annual General Meeting, Jun 26, 2026BML, Inc., Annual General Meeting, Jun 26, 2026.
お知らせ • May 09BML, Inc. to Report Fiscal Year 2026 Results on May 13, 2026BML, Inc. announced that they will report fiscal year 2026 results on May 13, 2026
Reported Earnings • 22hFirst quarter 2027 earnings released: EPS: JP¥52.82 (vs JP¥47.74 in 1Q 2026)First quarter 2027 results: EPS: JP¥52.82 (up from JP¥47.74 in 1Q 2026). Revenue: JP¥39.0b (up 2.7% from 1Q 2026). Net income: JP¥1.98b (up 6.3% from 1Q 2026). Profit margin: 5.1% (up from 4.9% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Declared Dividend • Jul 26Final dividend of JP¥62.50 announcedShareholders will receive a dividend of JP¥62.50. Ex-date: 29th September 2026 Payment date: 2nd December 2026 Dividend yield will be 331%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 03BML, Inc. to Report Q1, 2027 Results on Aug 07, 2026BML, Inc. announced that they will report Q1, 2027 results on Aug 07, 2026
Reported Earnings • May 14Full year 2026 earnings released: EPS: JP¥204 (vs JP¥161 in FY 2025)Full year 2026 results: EPS: JP¥204 (up from JP¥161 in FY 2025). Revenue: JP¥150.3b (up 4.9% from FY 2025). Net income: JP¥7.75b (up 24% from FY 2025). Profit margin: 5.2% (up from 4.4% in FY 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • May 13BML, Inc., Annual General Meeting, Jun 26, 2026BML, Inc., Annual General Meeting, Jun 26, 2026.
お知らせ • May 09BML, Inc. to Report Fiscal Year 2026 Results on May 13, 2026BML, Inc. announced that they will report fiscal year 2026 results on May 13, 2026
Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 30 June 2026. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.8%).
Reported Earnings • Feb 08Third quarter 2026 earnings released: EPS: JP¥62.19 (vs JP¥47.02 in 3Q 2025)Third quarter 2026 results: EPS: JP¥62.19 (up from JP¥47.02 in 3Q 2025). Revenue: JP¥38.8b (up 4.4% from 3Q 2025). Net income: JP¥2.34b (up 28% from 3Q 2025). Profit margin: 6.0% (up from 4.9% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Declared Dividend • Dec 03First half dividend of JP¥60.00 announcedShareholders will receive a dividend of JP¥60.00. Ex-date: 30th March 2026 Payment date: 30th June 2026 Dividend yield will be 293%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (50% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Nov 09Second quarter 2026 earnings released: EPS: JP¥61.81 (vs JP¥44.08 in 2Q 2025)Second quarter 2026 results: EPS: JP¥61.81 (up from JP¥44.08 in 2Q 2025). Revenue: JP¥37.6b (up 5.1% from 2Q 2025). Net income: JP¥2.36b (up 37% from 2Q 2025). Profit margin: 6.3% (up from 4.8% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 29 September 2025. Payment date: 03 December 2025. Payout ratio is a comfortable 61% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (2.5%).
お知らせ • Sep 03+ 1 more updateBML, Inc. to Report Q3, 2026 Results on Feb 06, 2026BML, Inc. announced that they will report Q3, 2026 results on Feb 06, 2026
Reported Earnings • Aug 10First quarter 2026 earnings released: EPS: JP¥47.74 (vs JP¥43.79 in 1Q 2025)First quarter 2026 results: EPS: JP¥47.74 (up from JP¥43.79 in 1Q 2025). Revenue: JP¥38.0b (up 6.8% from 1Q 2025). Net income: JP¥1.86b (up 9.1% from 1Q 2025). Profit margin: 4.9% (up from 4.8% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Declared Dividend • Jul 09Final dividend of JP¥60.00 announcedShareholders will receive a dividend of JP¥60.00. Ex-date: 29th September 2025 Payment date: 3rd December 2025 Dividend yield will be 321%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥161 (vs JP¥155 in FY 2024)Full year 2025 results: EPS: JP¥161 (up from JP¥155 in FY 2024). Revenue: JP¥143.2b (up 3.8% from FY 2024). Net income: JP¥6.26b (up 3.8% from FY 2024). Profit margin: 4.4% (in line with FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 03BML, Inc. to Report Q1, 2026 Results on Aug 08, 2025BML, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025
Buy Or Sell Opportunity • May 14Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.0% to €16.80. The fair value is estimated to be €21.29, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 65%. Revenue is forecast to grow by 6.2% in 2 years. Earnings are forecast to grow by 8.6% in the next 2 years.
Reported Earnings • May 11Full year 2025 earnings released: EPS: JP¥161 (vs JP¥155 in FY 2024)Full year 2025 results: EPS: JP¥161 (up from JP¥155 in FY 2024). Revenue: JP¥143.2b (up 3.8% from FY 2024). Net income: JP¥6.26b (up 3.8% from FY 2024). Profit margin: 4.4% (in line with FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance.
お知らせ • May 09BML, Inc., Annual General Meeting, Jun 27, 2025BML, Inc., Annual General Meeting, Jun 27, 2025.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥70.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 30 June 2025. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 4.7%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (2.7%).
お知らせ • Mar 04BML, Inc. to Report Fiscal Year 2025 Results on May 09, 2025BML, Inc. announced that they will report fiscal year 2025 results on May 09, 2025
New Risk • Feb 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risk Paying a dividend despite having no free cash flows.
Reported Earnings • Feb 09Third quarter 2025 earnings released: EPS: JP¥47.02 (vs JP¥47.58 in 3Q 2024)Third quarter 2025 results: EPS: JP¥47.02 (down from JP¥47.58 in 3Q 2024). Revenue: JP¥37.2b (up 6.0% from 3Q 2024). Net income: JP¥1.83b (down 1.1% from 3Q 2024). Profit margin: 4.9% (down from 5.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: JP¥44.08 (vs JP¥40.00 in 2Q 2024)Second quarter 2025 results: EPS: JP¥44.08 (up from JP¥40.00 in 2Q 2024). Revenue: JP¥35.8b (up 2.7% from 2Q 2024). Net income: JP¥1.72b (up 10% from 2Q 2024). Profit margin: 4.8% (up from 4.5% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 20Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 52% but the company is not cash flow positive. Trailing yield: 3.7%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.0%).
お知らせ • Aug 28+ 1 more updateBML, Inc. to Report Q2, 2025 Results on Nov 08, 2024BML, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024
Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: JP¥43.79 (vs JP¥46.08 in 1Q 2024)First quarter 2025 results: EPS: JP¥43.79 (down from JP¥46.08 in 1Q 2024). Revenue: JP¥35.6b (flat on 1Q 2024). Net income: JP¥1.71b (down 5.0% from 1Q 2024). Profit margin: 4.8% (down from 5.1% in 1Q 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 06BML, Inc. to Report Q1, 2025 Results on Aug 09, 2024BML, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024
Reported Earnings • May 13Full year 2024 earnings released: EPS: JP¥155 (vs JP¥396 in FY 2023)Full year 2024 results: EPS: JP¥155 (down from JP¥396 in FY 2023). Revenue: JP¥138.0b (down 14% from FY 2023). Net income: JP¥6.03b (down 61% from FY 2023). Profit margin: 4.4% (down from 9.8% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
お知らせ • May 12BML, Inc., Annual General Meeting, Jun 27, 2024BML, Inc., Annual General Meeting, Jun 27, 2024.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 42% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (3.2%).
お知らせ • Mar 02BML, Inc. to Report Fiscal Year 2024 Results on May 10, 2024BML, Inc. announced that they will report fiscal year 2024 results on May 10, 2024
New Risk • Feb 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.3% net profit margin).
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥47.58 (vs JP¥76.57 in 3Q 2023)Third quarter 2024 results: EPS: JP¥47.58 (down from JP¥76.57 in 3Q 2023). Revenue: JP¥35.1b (down 13% from 3Q 2023). Net income: JP¥1.86b (down 38% from 3Q 2023). Profit margin: 5.3% (down from 7.5% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.4% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 16% per year.
New Risk • Dec 17New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (5.9% net profit margin).
Reported Earnings • Nov 12Second quarter 2024 earnings released: EPS: JP¥40.00 (vs JP¥143 in 2Q 2023)Second quarter 2024 results: EPS: JP¥40.00 (down from JP¥143 in 2Q 2023). Revenue: JP¥34.8b (down 19% from 2Q 2023). Net income: JP¥1.56b (down 72% from 2Q 2023). Profit margin: 4.5% (down from 13% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 1.0% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥40.00 per share at 2.9% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 04 December 2023. Payout ratio is a comfortable 25% and the cash payout ratio is 94%. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.9%).
お知らせ • Aug 30BML, Inc. to Report Q2, 2024 Results on Feb 09, 2024BML, Inc. announced that they will report Q2, 2024 results on Feb 09, 2024
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥46.08 (vs JP¥119 in 1Q 2023)First quarter 2024 results: EPS: JP¥46.08 (down from JP¥119 in 1Q 2023). Revenue: JP¥35.3b (down 13% from 1Q 2023). Net income: JP¥1.80b (down 62% from 1Q 2023). Profit margin: 5.1% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • May 31BML, Inc. to Report Q1, 2024 Results on Aug 10, 2023BML, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
Reported Earnings • May 16Full year 2023 earnings released: EPS: JP¥396 (vs JP¥833 in FY 2022)Full year 2023 results: EPS: JP¥396 (down from JP¥833 in FY 2022). Revenue: JP¥159.5b (down 14% from FY 2022). Net income: JP¥15.6b (down 54% from FY 2022). Profit margin: 9.8% (down from 18% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • May 14BML, Inc., Annual General Meeting, Jun 29, 2023BML, Inc., Annual General Meeting, Jun 29, 2023.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per share at 2.6% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (3.4%).
Buying Opportunity • Feb 28Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.2%. The fair value is estimated to be €27.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 52%. For the next 3 years, revenue is forecast to decline by 0.8% per annum. Earnings is also forecast to decline by 6.7% per annum over the same time period.
Reported Earnings • Feb 13Third quarter 2023 earnings released: EPS: JP¥76.57 (vs JP¥131 in 3Q 2022)Third quarter 2023 results: EPS: JP¥76.57 (down from JP¥131 in 3Q 2022). Revenue: JP¥40.2b (down 1.9% from 3Q 2022). Net income: JP¥3.01b (down 43% from 3Q 2022). Profit margin: 7.5% (down from 13% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Feb 11BML, Inc. (TSE:4694) announces an Equity Buyback for 350,000 shares, representing 0.89% for ¥1,000 million.BML, Inc. (TSE:4694) announces a share repurchase program. Under the program, the company will repurchase up to 350,000 shares, representing 0.89% of its issued share capital for ¥1,000 million. The purpose of the program is to improve capital efficiency and enhance shareholder returns. The program is valid till April 30, 2023. As of January 31, 2023, the company had 39,279,662 shares issued (excluding treasury stock) and 3,333,964 shares in treasury.
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥143 (vs JP¥217 in 2Q 2022)Second quarter 2023 results: EPS: JP¥143 (down from JP¥217 in 2Q 2022). Revenue: JP¥43.2b (down 11% from 2Q 2022). Net income: JP¥5.61b (down 36% from 2Q 2022). Profit margin: 13% (down from 18% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Outside Director Shigeru Osawa was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 02 December 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (3.9%).
お知らせ • Aug 31+ 1 more updateBML, Inc. to Report Q2, 2023 Results on Nov 11, 2022BML, Inc. announced that they will report Q2, 2023 results on Nov 11, 2022
Reported Earnings • Aug 11First quarter 2023 earnings released: EPS: JP¥119 (vs JP¥244 in 1Q 2022)First quarter 2023 results: EPS: JP¥119 (down from JP¥244 in 1Q 2022). Revenue: JP¥40.5b (down 14% from 1Q 2022). Net income: JP¥4.72b (down 53% from 1Q 2022). Profit margin: 12% (down from 21% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the next year, revenue is expected to shrink by 20% compared to a 2.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 02BML, Inc. to Report Q1, 2023 Results on Aug 10, 2022BML, Inc. announced that they will report Q1, 2023 results on Aug 10, 2022
Reported Earnings • May 16Full year 2022 earnings released: EPS: JP¥833 (vs JP¥337 in FY 2021)Full year 2022 results: EPS: JP¥833 (up from JP¥337 in FY 2021). Revenue: JP¥186.1b (up 34% from FY 2021). Net income: JP¥33.7b (up 146% from FY 2021). Profit margin: 18% (up from 9.9% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 24% compared to a 5.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • May 15BML, Inc., Annual General Meeting, Jun 29, 2022BML, Inc., Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 3 highly experienced directors. 3 independent directors (5 non-independent directors). Managing Executive Officer & Director Masato Chikira was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 08BML, Inc. to Report Fiscal Year 2022 Results on May 13, 2022BML, Inc. announced that they will report fiscal year 2022 results on May 13, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥85.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (2.6%).
お知らせ • Mar 03BML, Inc. (TSE:4694) announces an Equity Buyback for 1,000,000 shares, representing 2.49% for ¥3,000 million.BML, Inc. (TSE:4694) announces a share repurchase program. Under the program, the company will repurchase up to 1,000,000 shares, representing 2.49% of its issued share capital for ¥3,000 million. The purpose of the program is to return of profits to shareholders as one of the important management issues, implement agile capital policies in response to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The program is valid till August 31, 2022. As of January 31, 2022, the company had 40,206,024 shares issued (excluding treasury stock) and 3,808,702 shares in treasury.
Reported Earnings • Feb 10Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥131 (up from JP¥126 in 3Q 2021). Revenue: JP¥41.0b (up 6.6% from 3Q 2021). Net income: JP¥5.29b (up 3.1% from 3Q 2021). Profit margin: 13% (in line with 3Q 2021). Revenue exceeded analyst estimates by 7.7%. Over the next year, revenue is expected to shrink by 18% compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS JP¥217 (vs JP¥83.75 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥48.6b (up 44% from 2Q 2021). Net income: JP¥8.82b (up 159% from 2Q 2021). Profit margin: 18% (up from 10% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥35.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 02 December 2021. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.3%).
Reported Earnings • Aug 13First quarter 2022 earnings released: EPS JP¥244 (vs JP¥2.73 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥47.1b (up 80% from 1Q 2021). Net income: JP¥9.94b (up JP¥9.83b from 1Q 2021). Profit margin: 21% (up from 0.4% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 15Full year 2021 earnings released: EPS JP¥337 (vs JP¥151 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥138.6b (up 15% from FY 2020). Net income: JP¥13.7b (up 115% from FY 2020). Profit margin: 9.9% (up from 5.3% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Mar 23Upcoming Dividend of JP¥50.00 Per ShareWill be paid on the 29th of June to those who are registered shareholders by the 30th of March. The trailing yield of 1.4% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (2.4%).
Reported Earnings • Feb 13Third quarter 2021 earnings released: EPS JP¥126 (vs JP¥40.86 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥38.5b (up 24% from 3Q 2020). Net income: JP¥5.14b (up 195% from 3Q 2020). Profit margin: 13% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Feb 13Revenue beats expectationsRevenue exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 1.5%, compared to a 3.5% growth forecast for the Healthcare industry in Germany.
Is New 90 Day High Low • Feb 11New 90-day high: €29.70The company is up 18% from its price of €25.18 on 12 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.25 per share.
Is New 90 Day High Low • Jan 21New 90-day high: €28.58The company is up 19% from its price of €24.11 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.80 per share.
お知らせ • Dec 13BML, Inc. to Report Q3, 2021 Results on Feb 10, 2021BML, Inc. announced that they will report Q3, 2021 results on Feb 10, 2021
Is New 90 Day High Low • Dec 12New 90-day high: €27.92The company is up 22% from its price of €22.94 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €37.58 per share.
Is New 90 Day High Low • Nov 21New 90-day high: €26.48The company is up 21% from its price of €21.82 on 21 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.58 per share.
Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectationsRevenue exceeded analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 4.3%, compared to a 4.4% growth forecast for the Healthcare industry in Germany.
Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS JP¥83.75The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥33.7b (up 8.5% from 2Q 2020). Net income: JP¥3.40b (up 76% from 2Q 2020). Profit margin: 10% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Sep 22New 90-day high: €24.23The company is up 2.0% from its price of €23.78 on 24 June 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.04 per share.
お知らせ • Aug 30BML, Inc. to Report Q2, 2021 Results on Nov 10, 2020BML, Inc. announced that they will report Q2, 2021 results on Nov 10, 2020
